Johnson & Johnson (JNJ) Offering Possible 19.47% Return Over the Next 27 Calendar Days

Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $145.00 short put and a strike $135.00 long put offers a potential 19.47% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $145.00 by expiration. The full premium credit of $1.63 would be kept by the premium seller. The risk of $8.37 would be incurred if the stock dropped below the $135.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 70.64 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Johnson & Johnson

Johnson & Johnson's Late-Stage Trial Of Single Dose COVID-19 Vaccine Fully Enrolled
Fri, 18 Dec 2020 06:45:59 +0000
Johnson & Johnson (NYSE: JNJ) has completed the participant enrollment for the Phase 3 trials of its single-dose COVID-19 vaccine, the company said in a statement Thursday.What Happened: JNJ has enrolled roughly 45,000 participants in the “Ensemble” trial, which is being conducted by its Janssen unit.The pharma company expects interim data from the trial by the end of January. It anticipates applying for emergency use authorization with the U.S. Food and Drug Administration in February if the study shows the vaccine to be effective.JNJ said that a separate Phase 3 trial for its investigational Janssen COVID-19 vaccine candidate by Jansen is ongoing to explore a two-dose regimen. Based on an earlier report, the “Ensemble 2” trial will complete the participants' recruitment by March.Why It Matters: The “Ensemble” trial was paused for a week in October when a participant developed an unexplained illness. JNJ resumed the trial after no clear cause of the illness was found.JNJ vaccine is one of the six vaccines expected to get a regulatory nod by the first quarter, according to Bill Gates. U.S. health officials are also offering logistical support to vaccine makers for the speedy delivery and efficient supply chain as the demand rises.Moderna Inc (NASDAQ: MRNA) secured the nod of the FDA advisory panel for its experimental COVID-19 vaccine on Thursday. The FDA typically concurs with the advisory panel's recommendations and EUA could arrive on Friday. Moderna's COVID-19 vaccine would the second such to be available in the United States after Pfizer Inc. (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX).Price Action: JNJ shares closed 2.64% higher at $153.62 on Thursday.See more from Benzinga * Click here for options trades from Benzinga * Alphabet-Backed GoCardless Nears B Valuation In Latest Funding Round: CNBC * Robinhood ‘Does Not Act In Best Investor Interest,' Massachusetts Securities Watchdog Alleges(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

J&J says late-stage COVID-19 vaccine trial fully enrolled
Fri, 18 Dec 2020 02:49:58 +0000
Johnson & Johnson said on Thursday it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate. The study, named Ensemble, has enrolled about 45,000 participants and is being conducted by its unit Janssen, J&J said https://www.jnj.com/our-company/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-is-fully-enrolled in a statement, adding that it expects interim data from the trial by the end of January 2021. J&J also said it plans to submit an emergency use authorization application to the U.S. Food and Drug Administration (FDA) in February if the data from the study is safe and effective.

Stock Market Today: With Eyes Only for Stimulus, Investors Keep Buying
Thu, 17 Dec 2020 21:47:59 +0000
Wall Street kept its sights squarely on the high likelihood of a stimulus bill Thursday, ignoring discouraging jobs and small business data.

A new coalition takes on social justice in medicine
Thu, 17 Dec 2020 17:29:10 +0000
A new organization – the Preparedness and Treatment Equity Coalition – is looking to use data and new metrics to bring more equity to healthcare.

Here's What You Need to Know Before Buying Coronavirus Vaccine Stocks
Thu, 17 Dec 2020 14:51:00 +0000
If you're interested in buying coronavirus vaccine stocks, there still are plenty of opportunities. In this Motley Fool Live video recorded on Dec. 11, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss important factors to consider before you get started. Corinne Cardina: What are three things you think investors should consider before buying a coronavirus vaccine stock?

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.